Resúmenes de trabajos publicados en otras revistas by Revista de Medicina
109 REV MED UNIV NAVARRA/VOL. 45, Nº 4, 2001, 10-14 11
RESÚMENES DE TRABAJOS PUBLICADOS EN OTRAS REVISTAS
64 REV MED UNIV NAVARRA/VOL. 45, Nº 4, 2001, 64-65 224
Abstract of:
Infection and Immunity, Nov 1999, p.6181-6186
The permeability of the outer membrane (OM) to hydrophobic
probes and its susceptibility to bactericidal cationic peptides
were investigated for natural rough Brucella ovis and for mutant
rough Brucella abortus strains. The OM of B. ovis displayed an
abrupt and faster kinetic profile than rough B. abortus during
the uptake of the hydrophobic probe N-phenyl-naphthylamine.
B. ovis was more sensitive than rough B. abortus to the action
of cationic peptides. Bactenecins 5 and 7 induced morphologi-
cal alterations on the OMs of both rough Brucella strains. B. ovis
lipopolysaccharide (LPS) captured considerably more polymyx-
in B than LPSs from both rough and smooth B. abortus strains.
Polymyxin B, poly-L-Iysine, and poly-L-ornithine produced a
thick coating on the surfaces of both strains, which was more
evident in B. ovis than in rough B. abortus. The distinct func-
tional properties of the OMs of these two rough strains correlate
with some structural differences of their OMs and with their dif-
ferent biological behaviors in animals and culture cells.
The Outer Membrane of Brucella ovis Shows Increased Permeability to Hydrophobic
Probes and Is More Susceptible to Cationic Peptides than Are the Outer 
Membranes of Mutant Rough Brucella abortus Strains
Enrique Freer1, Javier Fizarro-Cerdá2, Andrej Weintraub3, José-Antonio Bengoechea4, Ignacio Moriyón4, 
Kjell Hultenby5, Jean-Pierre Gorvel2 and Edgardo Moreno6
Unidad de Microscopía Electrónica, Universidad de Costa Rica, San José1, and Programa de Investigación en Enfermedades Tropicales, 
Escuela de Medicina Veterinaria, Universidad Nacional, Heredia6, Costa Rica: Centre d'Immunologie de Marseille-Luminy, Marseille-Luminy, France2;
Department of Immunology. Microbiology, Pathology and Infectious Diseases, Division of Clinical Bacteriology Karolinska Institute 3, 
and Clinical Research Center5, Huddinge University Hospitat, Huddinge, Sweden; and Departamento de Microbiología, 
Universidad de Navarra, Pamplona, Spain4
Abstract of:
J Am Coll Cardiol. 1999 Nov 1; 34(5): 1498-506
Objective: The purpose of this study was to test the hypothesis
that stent implantation in de novo coronary artery lesions would
result in lower restenosis rates and better long-term clinical out-
comes than balloon angioplasty. 
Background: Placement of an intracoronary stent, as compared
with balloon angioplasty, has proven to reduce the rate of
restenosis. However, the long-term clinical benefit of stenting
over angioplasty has not been assessed in large randomized tri-
als. 
Methods: We randomly assigned 452 patients with either stable
(129 patients) or unstable (323 patients) angina pectoris to elec-
tive stent implantation (229 patients) or standard balloon angio-
plasty (223 patients). Coronary angiography was performed at
baseline, immediately after the procedure and six months later.
End points were the rate of restenosis at six months and a com-
posite of death, myocardial infarction (MI) and target vessel
revascularization over four years of follow-up. 
Results: Procedural success rate was achieved in 84% and 95%
(balloon angioplasty vs. stent, respectively). The increase in the
minimal luminal diameter was greater in the stent group both
after the intervention (2.02 +/- 0.6 mm vs. 1.43 +/- 0.6 mm in the
angioplasty group; p <0.0001), and at six-month follow-up (1.98
+/- 0.7 mm vs. 1.63 +/- 0.7 mm; p < 0.001). The corresponding
restenosis rates were 22% and 37%, respectively (p <0.002).
After four years, no differences in mortality (2.7% vs. 2.4%) and
nonfatal MI (2.2% vs. 2.8%) were found between the stent and
the angioplasty groups, respectively. However, the requirement
for further revascularization procedures of the target lesions was
significantly reduced in the stent group (12% vs. 25% in the
angioplasty group; relative risk 0.49, 95% confidence interval
0.32 to 0.75, p = 0.0006); most of the repeat procedures (84%)
were carried out within six months of entry into the study.
Conclusions: Patients who received an intracoronary stent
showed a lower rate of restenosis than those treated with con-
ventional balloon angioplasty. The benefit of stenting was main-
tained four years after implantation, as manifested by a signifi-
cant reduction in the need for repeat revascularization. 
Randomized comparison of coronary stent implantation and balloon angioplasty 
in the treatment of de novo coronary artery lesions (START): a four-year 
follow-up
Betriu A, Masotti M, Serra A, Alonso J, Fernández Aviles F, Gimeno F, Colman T, Zueco J, 
Delcan JL, García E, Calabuig J
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Do the low molecular weight heparins improve efficacy and safety 
of the treatment of deep venous thrombosis? A meta-analysis
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Abstract of:
Haematologica 2000;85:935-942
Background and Objectives: We compared the efficacy and safe-
ty of low molecular weight heparins (LMWH) and unfractionated
heparin (UFH) in the treatment of deep venous thrombosis (DVT).
A comparison between two daily subcutaneous injections of
LMWH against a single injection was also performed.
Design and Methods: The study was performed by a meta-
analysis. Clot improvement in venography, recurrency, total
mortality and major hemorrhages were assessed in 4,472
patients with DVT from 21 studies treated with subcutaneous
LMWH or UFH.
Results: An improvement in clot reduction (odds ratio 0.73, 95%
confidence interval 0.59 to 0.90, p = 0.004), a decrease in total
mortality (0.68, 0.50 to 0.91, p = 0.012) and a lower incidence
of hemorrhage (0.65, 0.43 to 0.98, p = 0.047) were observed in
LMWH treated patients. There were no differences in recur-
rences (0.78, 0.59 to 1.04, p = 0.10). A single dose of LMWH
was better than two in reducing major bleeding (x2 = 4.99, p =
0.025); however, the two dose regimen was more effective in
clot reduction (x2 = 8.56, p = 0.004).
Interpretation and Conclusions: LMWH is superior to UFH in
terms of safety and efficacy. A single daily dose of LMWH dose
is a suitable therapeutic regimen and could facilitate the outpa-
tient treatment of venous thromboembolism.
Abstract of:
Allergol et Immunopathol 2000;28:207-12
Background: The ISAAC (International Study of Asthma and
Allergies in Childhood) was thought in order to maximize the
value of epidemiological research into asthma and allergic dis-
eases in childhood, establishing a standardized methodology
and facilitating collaboration and comparison between several
countries.
Methods and Results: The written questionnaires in the group of
children aged 6-7 years was answered by the parents and the
group of children aged 13-14 years self-completed the written
questionnaires.
Results: 3.040 children aged 1 3-1 4 years answered the ques-
tionnaire and 3.002 in the group aged 6-7 years. In the group
of children aged 13-14, 49.7% referred rhinitis symptoms
some time, and 15.6% in the 6-7 year old group. The preva-
lence of nasal symptoms in the last year was 35.5% in the 13-
l4year group and 1 0.6% in the 6-7 year group. The presence
of nasal symptoms was more frequent in winter. The preva-
lence of seasonal allergic rhinitis (hay fever) was 6.1 % in the
13-14 year group and 4.8% in the group of children aged 6-7
years.
Conclusions: These results can contribute to a better control of
some factors and to future studies where the etiology and inci-
dence of the disease could be investigated.
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